BioCentury | Mar 29, 2019
Company News

Ares Life Sciences to take Stallergenes Greer private

...Sciences agreed to take allergy company Stallergenes Greer private. Ares Life Sciences (Geneva, Switzerland) will pay Stallergenes Greer plc...
...deal's close, the biotech will no longer be listed on Euronext. Shannon Lehnbeuter, Staff Writer Ares Life Sciences Stallergenes Greer plc...
BioCentury | Nov 30, 2018
Clinical News

Stallergenes Phase III data for sublingual allergy tablet support U.S. and EU submissions

...presented at the European Academy of Allergy and Clinical Immunology meeting in Lisbon in June. Stallergenes Greer plc...
...year; safety Status: Phase III data Milestone: NA Brian Moy Actair (S-524101, STG320, house dust mites sublingual tablet) Stallergenes Greer plc STAGR320...
BioCentury | Jul 25, 2018
Company News

Management Tracks: Albireo, ObsEva

...Inc. (NASDAQ:NERV) hired Devin Smith as SVP and general counsel. He was general counsel at Stallergenes Greer plc...
BioCentury | Jun 18, 2018
Company News

Management tracks: Ionis, Albireo

...Albireo Pharma Inc. (NASDAQ:ALBO) hired Jason Duncan as general counsel. He was general counsel at Stallergenes Greer plc...
BioCentury | Dec 12, 2017
Company News

Management tracks: Achaogen, Minerva

...Russell will become president. Russell was president and CEO of the North American subsidiary of Stallergenes Greer plc...
BioCentury | Sep 29, 2017
Clinical News

Stallergenes completes enrollment in Phase III trial of dust mite allergy tablet Actair

...commercialize the product in Japan and Taiwan from Stallergenes (see BioCentury, Sept. 13, 2010 ). Stallergenes Greer plc...
...score; safety Status: Completed Phase III enrollment Milestone: Submit BLA (2019) Alicia Parker Actair house dust mites sublingual tablet S-524101 STG320 Stallergenes Greer plc...
BioCentury | Mar 31, 2017
Clinical News

Actair regulatory update

...commercialize the product in Japan and Taiwan from Stallergenes (see BioCentury, Sept. 13, 2010 ). Stallergenes Greer plc...
...Actair house dust mite sublingual tablet ( S-524101 , STG320) Business: Inflammation Julian Zhu Actair S-524101 STG320 Shionogi & Co. Ltd. Stallergenes Greer plc...
BioCentury | Mar 8, 2017
Company News

Management tracks

...oncology at Evotec AG (Xetra:EVT), and Beaumont was SVP, head of global clinical development at Stallergenes Greer plc...
BioCentury | Feb 3, 2017
Clinical News

STG320: Ph III data

...from Stallergenes (see BioCentury, Sept. 13, 2010 ). Shionogi & Co. Ltd. (Tokyo:4507), Osaka, Japan Stallergenes Greer plc...
...Status: Phase III data Milestone: NA Jaime De Leon Actair House dust mites sublingual immunotherapy tablet S-524101 Shionogi & Co. Ltd. Stallergenes Greer plc STG320...
BioCentury | Dec 5, 2015
Company News

Management tracks

...Euronext:ABLX) named Robert Zeldin CMO. He was SVP and head of global clinical development at Stallergenes Greer plc...
Items per page:
1 - 10 of 14
BioCentury | Mar 29, 2019
Company News

Ares Life Sciences to take Stallergenes Greer private

...Sciences agreed to take allergy company Stallergenes Greer private. Ares Life Sciences (Geneva, Switzerland) will pay Stallergenes Greer plc...
...deal's close, the biotech will no longer be listed on Euronext. Shannon Lehnbeuter, Staff Writer Ares Life Sciences Stallergenes Greer plc...
BioCentury | Nov 30, 2018
Clinical News

Stallergenes Phase III data for sublingual allergy tablet support U.S. and EU submissions

...presented at the European Academy of Allergy and Clinical Immunology meeting in Lisbon in June. Stallergenes Greer plc...
...year; safety Status: Phase III data Milestone: NA Brian Moy Actair (S-524101, STG320, house dust mites sublingual tablet) Stallergenes Greer plc STAGR320...
BioCentury | Jul 25, 2018
Company News

Management Tracks: Albireo, ObsEva

...Inc. (NASDAQ:NERV) hired Devin Smith as SVP and general counsel. He was general counsel at Stallergenes Greer plc...
BioCentury | Jun 18, 2018
Company News

Management tracks: Ionis, Albireo

...Albireo Pharma Inc. (NASDAQ:ALBO) hired Jason Duncan as general counsel. He was general counsel at Stallergenes Greer plc...
BioCentury | Dec 12, 2017
Company News

Management tracks: Achaogen, Minerva

...Russell will become president. Russell was president and CEO of the North American subsidiary of Stallergenes Greer plc...
BioCentury | Sep 29, 2017
Clinical News

Stallergenes completes enrollment in Phase III trial of dust mite allergy tablet Actair

...commercialize the product in Japan and Taiwan from Stallergenes (see BioCentury, Sept. 13, 2010 ). Stallergenes Greer plc...
...score; safety Status: Completed Phase III enrollment Milestone: Submit BLA (2019) Alicia Parker Actair house dust mites sublingual tablet S-524101 STG320 Stallergenes Greer plc...
BioCentury | Mar 31, 2017
Clinical News

Actair regulatory update

...commercialize the product in Japan and Taiwan from Stallergenes (see BioCentury, Sept. 13, 2010 ). Stallergenes Greer plc...
...Actair house dust mite sublingual tablet ( S-524101 , STG320) Business: Inflammation Julian Zhu Actair S-524101 STG320 Shionogi & Co. Ltd. Stallergenes Greer plc...
BioCentury | Mar 8, 2017
Company News

Management tracks

...oncology at Evotec AG (Xetra:EVT), and Beaumont was SVP, head of global clinical development at Stallergenes Greer plc...
BioCentury | Feb 3, 2017
Clinical News

STG320: Ph III data

...from Stallergenes (see BioCentury, Sept. 13, 2010 ). Shionogi & Co. Ltd. (Tokyo:4507), Osaka, Japan Stallergenes Greer plc...
...Status: Phase III data Milestone: NA Jaime De Leon Actair House dust mites sublingual immunotherapy tablet S-524101 Shionogi & Co. Ltd. Stallergenes Greer plc STG320...
BioCentury | Dec 5, 2015
Company News

Management tracks

...Euronext:ABLX) named Robert Zeldin CMO. He was SVP and head of global clinical development at Stallergenes Greer plc...
Items per page:
1 - 10 of 14